secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002295
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora updates pipeline; KIO-301 Phase 1b results expected 1H 2023
-----------------------------------------------------------------

- KIO-301 (RP) Phase 1b ABACUS trial first patient dosed Q4 2022; preliminary results expected 1H 2023.
- KIO-101 (OPRA+) Phase 2 trial conditionally approved; first patient enrollment planned 1H 2023.
- KIO-201 (PCED) Phase 2 trial fully enrolled Q4 2022; results and FDA registration dialogue expected 1H 2023.
- Raised ~$20M gross in past 18 months; received $1.2M in R&D tax credits.
- Appointed Melissa Tosca as EVP Finance; strengthened SEC reporting procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465923002295/0001104659-23-002295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465923002295/tm232667d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer